Base de dados : MEDLINE
Pesquisa : C04.692 [Categoria DeCS]
Referências encontradas : 12073 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1208 ir para página                         

  1 / 12073 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28954302
[Au] Autor:Fidler MM; Reulen RC; Winter DL; Allodji RS; Bagnasco F; Bárdi E; Bautz A; Bright CJ; Byrne J; Feijen EAM; Garwicz S; Grabow D; Gudmundsdottir T; Guha J; Haddy N; Jankovic M; Kaatsch P; Kaiser M; Kuonen R; Linge H; Maule M; Merletti F; Øfstaas H; Ronckers CM; Skinner R; Teepen J; Terenziani M; Vu-Bezin G; Wesenberg F; Wiebe T; Jakab Z; Haupt R; Lähteenmäki P; Zaletel LZ; Kuehni CE; Winther JF; de Vathaire F; Kremer LC; Hjorth L; Hawkins MM
[Ad] Endereço:Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK; Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France; Cancer and Radiation Team, U1018 INSERM, Villejuif, France; Epidemiology and Biosta
[Ti] Título:Risk of Subsequent Bone Cancers Among 69 460 Five-Year Survivors of Childhood and Adolescent Cancer in Europe.
[So] Source:J Natl Cancer Inst;110(2), 2018 Feb 01.
[Is] ISSN:1460-2105
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Introduction: We investigate the risks of subsequent primary bone cancers after childhood and adolescent cancer in 12 European countries. For the first time, we satisfactorily address the risks beyond 40 years from diagnosis and beyond 40 years of age among all survivors. Methods: This largest-ever assembled cohort comprises 69 460 five-year survivors of cancer diagnosed before age 20 years. Standardized incidence ratios, absolute excess risks, and multivariable-adjusted relative risks and relative excess risks were calculated. All statistical tests were two-sided. Results: Overall, survivors were 21.65 times (95% confidence interval = 18.97 to 24.60 times) more likely to be diagnosed with a subsequent primary bone cancer than expected from the general population. The greatest excess numbers of bone cancers were observed after retinoblastoma, bone sarcoma, and soft tissue sarcoma. The excess number of bone cancers declined linearly with both years since diagnosis and attained age (all P < .05). Beyond 40 years from diagnosis and age 40 years, there were at most 0.45 excess bone cancers among all survivors per 10 000 person-years at risk; beyond 30 years from diagnosis and age 30 years, there were at most 5.02 excess bone cancers after each of retinoblastoma, bone sarcoma, and soft tissue sarcoma, per 10 000 person-years at risk. Conclusions: For all survivors combined and the cancer groups with the greatest excess number of bone cancers, the excess numbers observed declined with both age and years from diagnosis. These results provide novel, reliable, and unbiased information about risks and risk factors among long-term survivors of childhood and adolescent cancer.
[Mh] Termos MeSH primário: Neoplasias Ósseas/epidemiologia
Segunda Neoplasia Primária/epidemiologia
Sobreviventes/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Criança
Estudos de Coortes
Europa (Continente)/epidemiologia
Feminino
Seguimentos
Seres Humanos
Masculino
Osteossarcoma/epidemiologia
Retinoblastoma/epidemiologia
Sarcoma/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE
[do] DOI:10.1093/jnci/djx165


  2 / 12073 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28922787
[Au] Autor:Blok EJ; Kroep JR; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; Putter H; van den Bosch J; Maartense E; van Leeuwen-Stok AE; Liefers GJ; Nortier JWR; Rutgers EJT; van de Velde CJH; IDEAL Study Group
[Ad] Endereço:Departments of Surgery, Medical Oncology, and Medical Statistics, Leiden University Medical Center, Leiden, Netherlands; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands; Department of Internal Medicine, Reinier de Graaff Hospital, Delft, the Netherlands; Dutch
[Ti] Título:Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
[So] Source:J Natl Cancer Inst;110(1), 2018 Jan 01.
[Is] ISSN:1460-2105
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: The optimal duration of extended endocrine therapy beyond five years after initial aromatase inhibitor-based adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer is still unknown. Therefore, we conducted a clinical trial to compare two different extended endocrine therapy durations. Methods: In the randomized phase III IDEAL trial, postmenopausal patients with hormone receptor-positive breast cancer were randomly allocated to either 2.5 or five years of letrozole after the initial five years of any endocrine therapy. The primary end point was disease free survival (DFS), and secondary end points were overall survival (OS), distant metastasis-free interval (DMFi), new primary breast cancer, and safety. Hazard ratios (HRs) were determined using Cox regression analysis. All analyses were by intention-to-treat principle. Results: A total of 1824 patients were assigned to either 2.5 years (n = 909) or five years (n = 915) of letrozole, with a median follow-up of 6.6 years. A DFS event occurred in 152 patients in the five-year group, compared with 163 patients in the 2.5-year group (HR = 0.92, 95% confidence interval [CI] = 0.74 to 1.16). OS (HR = 1.04, 95% CI = 0.78 to 1.38) and DMFi (HR = 1.06, 95% CI = 0.78 to 1.45) were not different between both groups. A reduction in occurrence of second primary breast cancer was observed with five years of treatment (HR = 0.39, 95% CI = 0.19 to 0.81). Subgroup analysis did not identify patients who benefit from five-year extended therapy. Conclusion: This study showed no superiority of five years over 2.5 years of extended adjuvant letrozole after an initial five years of adjuvant endocrine therapy.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Neoplasias da Mama/terapia
Carcinoma Ductal de Mama/terapia
Carcinoma Intraductal não Infiltrante/terapia
Recidiva Local de Neoplasia/prevenção & controle
Segunda Neoplasia Primária/prevenção & controle
Nitrilos/administração & dosagem
Triazóis/administração & dosagem
[Mh] Termos MeSH secundário: Idoso
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Inibidores da Aromatase/administração & dosagem
Neoplasias da Mama/química
Neoplasias da Mama/patologia
Carcinoma Ductal de Mama/química
Carcinoma Ductal de Mama/prevenção & controle
Carcinoma Ductal de Mama/secundário
Carcinoma Intraductal não Infiltrante/prevenção & controle
Quimioterapia Adjuvante/efeitos adversos
Intervalo Livre de Doença
Feminino
Seguimentos
Seres Humanos
Mastectomia Segmentar
Meia-Idade
Nitrilos/efeitos adversos
Pós-Menopausa
Receptores Estrogênicos/análise
Receptores de Progesterona/análise
Taxa de Sobrevida
Tamoxifeno/administração & dosagem
Fatores de Tempo
Triazóis/efeitos adversos
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Aromatase Inhibitors); 0 (Nitriles); 0 (Receptors, Estrogen); 0 (Receptors, Progesterone); 0 (Triazoles); 094ZI81Y45 (Tamoxifen); 7LKK855W8I (letrozole)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170920
[St] Status:MEDLINE
[do] DOI:10.1093/jnci/djx134


  3 / 12073 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28922781
[Au] Autor:Goldvaser H; Barnes TA; Seruga B; Cescon DW; Ocaña A; Ribnikar D; Amir E
[Ad] Endereço:Division of Medical Oncology, University of Toronto and Princess Margaret Cancer Centre, Toronto, Canada; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia; Research Unit, Albacete University Hospi
[Ti] Título:Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.
[So] Source:J Natl Cancer Inst;110(1), 2018 Jan 01.
[Is] ISSN:1460-2105
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: A number of randomized controlled trials (RCTs) have reported improvement in breast cancer outcomes from extending treatment with aromatase inhibitors (AIs) beyond the initial five years after diagnosis. However, the toxicity profile of extended AIs is uncertain. Methods: We identified RCTs that compared extended AIs to placebo or no treatment using MEDLINE and a review of abstracts from key conferences between 2013 and 2016. Odds ratios (ORs), 95% confidence intervals (CIs), absolute risks, and the number needed to harm (NNH) were computed for prespecified safety and tolerability outcomes including cardiovascular events, bone fractures, second cancers (excluding new breast cancer), treatment discontinuation for adverse events, and death without recurrence. All statistical tests were two-sided. Results: Seven trials comprising 16 349 patients met the inclusion criteria. Longer treatment with AIs was associated with increased odds of cardiovascular events (OR = 1.18, 95% CI = 1.00 to 1.40, P = .05, NNH = 122), bone fractures (OR = 1.34, 95% CI = 1.16 to 1.55, P < .001, NNH = 72), and treatment discontinuation for adverse events (OR = 1.45, 95% CI = 1.25 to 1.68, P < .001, NNH = 21). Longer treatment with AIs did not influence the odds of either second malignancy (OR = 0.93, 95% CI = 0.73 to 1.18, P = .56) or deaths without breast cancer recurrence (OR = 1.11, 95% CI = 0.90 to 1.36, P = .34). Conclusions: Extended treatment with AIs is associated with an increased risk of cardiovascular events and bone fractures. There is no statistically significant increase in deaths without breast cancer recurrence among patients receiving longer treatment with AIs. These data should be taken into account when considering extended adjuvant AIs.
[Mh] Termos MeSH primário: Inibidores da Aromatase/efeitos adversos
Neoplasias da Mama/tratamento farmacológico
Doenças Cardiovasculares/epidemiologia
Quimioterapia Adjuvante/efeitos adversos
Fraturas Ósseas/epidemiologia
Segunda Neoplasia Primária/epidemiologia
[Mh] Termos MeSH secundário: Inibidores da Aromatase/administração & dosagem
Neoplasias da Mama/cirurgia
Quimioterapia Adjuvante/métodos
Feminino
Seres Humanos
Mortalidade
Ensaios Clínicos Controlados Aleatórios como Assunto
Fatores de Tempo
Suspensão de Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Aromatase Inhibitors)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170920
[St] Status:MEDLINE
[do] DOI:10.1093/jnci/djx141


  4 / 12073 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29480859
[Au] Autor:Hong YT; Hong KH
[Ad] Endereço:Department of Otolaryngology-HNS, Institute for Medical Science, Chonbuk National University, Chonbuk National University Hospital, Jeonju, South Korea.
[Ti] Título:Sequential occurrence of diffuse large B-cell lymphoma and carcinoma in the nasopharynx: A case report.
[So] Source:Medicine (Baltimore);97(2):e9595, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The sequential occurrence of the 2 malignancies development of nasopharyngeal carcinoma (NPC) and lymphoma is extremely rare and their coexistence raises the question of a common etiologic factor. CLINICAL FINDINGS/CLINICAL CONCERNS: A 71-year-old previously healthy man presented with diffuse large B-cell lymphoma (BCL) followed by NPC almost 2 years later with Epstein-Barr virus (EBV) positive. DIAGNOSIS: Endoscopic examination characterized a fixed, hard and nontender mass in the nasopharynx and biopsies were done. INTERVENTION: A patient successfully underwent chemotherapy for lymphoma and chemoradiation for carcinoma sequentially. OUTCOMES: He was followed up every 3 months for 1 year with endoscopic and radiological examinations. The nasopharynx mass was completely resolved after chemoradiation therapy. CONCLUSION: The presentation with diffuse large B-cell lymphoma (BCL) and NPC in this patient was perhaps caused by dual EBV infection or a different oncogenic mechanism.
[Mh] Termos MeSH primário: Carcinoma/tratamento farmacológico
Carcinoma/radioterapia
Infecções por Vírus Epstein-Barr/complicações
Linfoma Difuso de Grandes Células B/tratamento farmacológico
Neoplasias Nasofaríngeas/tratamento farmacológico
Neoplasias Nasofaríngeas/radioterapia
Segunda Neoplasia Primária/tratamento farmacológico
Segunda Neoplasia Primária/radioterapia
[Mh] Termos MeSH secundário: Idoso
Carcinoma/patologia
Carcinoma/virologia
Seres Humanos
Linfoma Difuso de Grandes Células B/diagnóstico por imagem
Linfoma Difuso de Grandes Células B/patologia
Linfoma Difuso de Grandes Células B/virologia
Masculino
Neoplasias Nasofaríngeas/patologia
Neoplasias Nasofaríngeas/virologia
Segunda Neoplasia Primária/patologia
Segunda Neoplasia Primária/virologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180227
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009595


  5 / 12073 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29252655
[Au] Autor:Park A; Cipriano CA; Hill K; Kyriakos M; McDonald DJ
[Ad] Endereço:Departments of Orthopaedic Surgery (A.P., C.A.C., and D.J.M.) and Pathology (K.H. and M.K.), Washington University School of Medicine, St. Louis, Missouri.
[Ti] Título:Malignant Transformation of a Giant Cell Tumor of Bone Treated with Denosumab: A Case Report.
[So] Source:JBJS Case Connect;6(3):e78, 2016 Jul-Sep.
[Is] ISSN:2160-3251
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CASE: Giant cell tumor (GCT) of bone was first described almost 200 years ago, but the optimal treatment continues to evolve. We present a patient with a pelvic GCT who was treated with embolization, 20 months of denosumab therapy, and resection. Histologically, the tumor consisted of degenerated GCT, bone, and fibrous tissue. After 7 months, the patient was found to have osteosarcoma at the site of the initial lesion as well as pulmonary metastases. CONCLUSION: The apparent malignant transformation of a GCT of bone treated initially with denosumab indicates that close follow-up is warranted.
[Mh] Termos MeSH primário: Conservadores da Densidade Óssea/efeitos adversos
Neoplasias Ósseas/patologia
Denosumab/efeitos adversos
Tumor de Células Gigantes do Osso/patologia
Segunda Neoplasia Primária/patologia
Osteossarcoma/patologia
Ossos Pélvicos/patologia
[Mh] Termos MeSH secundário: Adulto
Neoplasias Ósseas/diagnóstico por imagem
Neoplasias Ósseas/tratamento farmacológico
Neoplasias Ósseas/cirurgia
Transformação Celular Neoplásica
Evolução Fatal
Feminino
Tumor de Células Gigantes do Osso/diagnóstico por imagem
Tumor de Células Gigantes do Osso/tratamento farmacológico
Tumor de Células Gigantes do Osso/cirurgia
Seres Humanos
Segunda Neoplasia Primária/etiologia
Osteossarcoma/etiologia
Ossos Pélvicos/diagnóstico por imagem
Ossos Pélvicos/efeitos dos fármacos
Ossos Pélvicos/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bone Density Conservation Agents); 4EQZ6YO2HI (Denosumab)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171219
[St] Status:MEDLINE
[do] DOI:10.2106/JBJS.CC.16.00024


  6 / 12073 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28466487
[Au] Autor:Epperla N; Pham AQ; Burnette BL; Wiseman GA; Habermann TM; Macon WR; Ansell SM; Inwards DJ; Micallef IN; Johnston PB; Markovic SN; Porrata LF; Colgan JP; Ristow KM; Nowakowski GS; Witzig TE
[Ad] Endereço:Department of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
[Ti] Título:Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
[So] Source:Br J Haematol;178(3):427-433, 2017 08.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Histological transformation (HT) of follicular lymphoma (FL) to an aggressive lymphoma after chemotherapy remains a key issue. The incidence of HT after radioimmunotherapy (RIT) is unknown. This single institution study analysed the risk of HT in FL after treatment with yttrium-90 ibritumomab tiuxetan in 115 consecutive patients treated during 1987-2012. RIT was administered for progressive FL in 111 (97%) patients and as first-line therapy in the remaining 4. 28% (n = 32) had HT, occurring at a median of 60 months from diagnosis and 20 months after RIT. 48% (12/25) of patients who received fludarabine developed HT. The estimated 10-year risk of HT in the fludarabine and non-fludarabine groups was 67% and 26% respectively (P = 0·015). Only prior fludarabine was significantly associated with predicting the risk of HT after RIT. 8% (9/115) of patients developed therapy-related myelodysplastic syndrome/acute myeloid leukaemia (tMDS/AML) at a median of 41·4 months (range, 5-89). The estimated 10-year risk of tMDS/AML in non-fludarabine treated patients (n = 90) versus fludarabine treated (n = 25) was 13% and 29%, respectively. The estimated overall risk of FL undergoing HT at 10 years without fludarabine exposure appears similar to patients reported in the literature that have not received RIT. Patients with prior purine-analogue therapy are at significantly higher risk of HT.
[Mh] Termos MeSH primário: Leucemia Mieloide Aguda/etiologia
Linfoma Folicular/terapia
Síndromes Mielodisplásicas/etiologia
Segunda Neoplasia Primária/etiologia
Radioimunoterapia/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Anticorpos Monoclonais/efeitos adversos
Anticorpos Monoclonais/uso terapêutico
Quimioterapia Adjuvante/efeitos adversos
Bases de Dados Factuais
Feminino
Seres Humanos
Masculino
Meia-Idade
Neoplasias Induzidas por Radiação/etiologia
Radioimunoterapia/métodos
Fatores de Risco
Rituximab/efeitos adversos
Rituximab/uso terapêutico
Vidarabina/efeitos adversos
Vidarabina/análogos & derivados
Vidarabina/uso terapêutico
Adulto Jovem
Radioisótopos de Ítrio/efeitos adversos
Radioisótopos de Ítrio/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Yttrium Radioisotopes); 4F4X42SYQ6 (Rituximab); 4Q52C550XK (ibritumomab tiuxetan); FA2DM6879K (Vidarabine); P2K93U8740 (fludarabine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.14688


  7 / 12073 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29254594
[Au] Autor:Austin AM; Douglass MJJ; Nguyen GT; Penfold SN
[Ad] Endereço:Department of Physics, University of Adelaide, Adelaide, SA 5005, Australia. Electronic address: annabelle.austin@adelaide.edu.au.
[Ti] Título:A radiobiological Markov simulation tool for aiding decision making in proton therapy referral.
[So] Source:Phys Med;44:72-82, 2017 Dec.
[Is] ISSN:1724-191X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Proton therapy can be a highly effective strategy for the treatment of tumours. However, compared with X-ray therapy it is more expensive and has limited availability. In addition, it is not always clear whether it will benefit an individual patient more than a course of traditional X-ray therapy. Basing a treatment decision on outcomes of clinical trials can be difficult due to a shortage of data. Predictive modelling studies are becoming an attractive alternative to supplement clinical decisions. The aim of the current work is to present a Markov framework that compares clinical outcomes for proton and X-ray therapy. METHODS: A Markov model has been developed which estimates the radiobiological effect of a given treatment plan. This radiobiological effect is estimated using the tumour control probability (TCP), normal tissue complication probability (NTCP) and second primary cancer induction probability (SPCIP). These metrics are used as transition probabilities in the Markov chain. The clinical outcome is quantified by the quality adjusted life expectancy. To demonstrate functionality, the model was applied to a 6-year-old patient presenting with skull base chordoma. RESULTS: The model was successfully developed to compare clinical outcomes for proton and X-ray treatment plans. For the example patient considered, it was predicted that proton therapy would offer a significant advantage compared with volumetric modulated arc therapy in terms of survival and mitigating injuries. CONCLUSIONS: The functionality of the model was demonstrated using the example patient. The proposed Markov method may be a useful tool for deciding on a treatment strategy for individual patients.
[Mh] Termos MeSH primário: Tomada de Decisões
Cadeias de Markov
Terapia com Prótons
Radiobiologia
Encaminhamento e Consulta
[Mh] Termos MeSH secundário: Criança
Cordoma/radioterapia
Seres Humanos
Masculino
Segunda Neoplasia Primária/etiologia
Terapia com Prótons/efeitos adversos
Anos de Vida Ajustados por Qualidade de Vida
Neoplasias Cranianas/radioterapia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180130
[Lr] Data última revisão:
180130
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171220
[St] Status:MEDLINE


  8 / 12073 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28467332
[Au] Autor:Cecchini S; Azzoni C; Bottarelli L; Marchesi F; Rubichi F; Silini EM; Roncoroni L
[Ad] Endereço:Dipartimento di Scienze Chirurgiche, sezione di Clinica Chirurgica Generale e Terapia Chirurgica, Università degli studi di Parma, Via Gramsci n.14, 43100 Parma Italia.. ste.cecchini79@gmail.com.
[Ti] Título:Surgical treatment of multiple sporadic colorectal carcinoma.
[So] Source:Acta Biomed;88(1):39-44, 2017 Apr 28.
[Is] ISSN:0392-4203
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:AIM: Many aspects of the surgical management of multiple sporadic colorectal cancer syndrome, either synchronous and metachronous, remain to be cleared, in particular the prognostic influence of the extent of surgical resection. METHOD: A retrospective review was performed of patients diagnosed with multiple colorectal cancer from 1982 to May 2010. Clinical and pathologic data were collected and reviewed. Survival analysis was performed. RESULTS: We identified 23 patients with multiple sporadic colorectal cancers, of which 8 had synchronous (SC) and 15 metachronous cancers (MC). Of the MC patients, 2 (13%) had the second cancer within 2 years, 4 (27%) in the time period of 2-5 years and 9 (60%) after 5 years. Twenty-one patients underwent multiple segmental resections; 2 patients underwent subtotal colectomy. The 5-year overall survival rate of SC and MC patients was 100% and 87% (p<0.001) respectively. The 5-year overall survival rate of multiple segmental resection patients and subtotal colectomy was 94% and 75% (p=0.655) respectively. CONCLUSION: Either synchronous and metachronous MSCRC patients showed good prognosis independently from to the extent of resection. Our results support a less aggressive biological behaviour allowing a more conservative management. Multiple segmental colorectal resections seem appropriate from an oncologic point of view in MSCRC patients.
[Mh] Termos MeSH primário: Adenocarcinoma/cirurgia
Neoplasias Colorretais/cirurgia
Neoplasias Primárias Múltiplas/cirurgia
Segunda Neoplasia Primária/cirurgia
[Mh] Termos MeSH secundário: Adenocarcinoma/mortalidade
Adenocarcinoma/patologia
Idoso
Idoso de 80 Anos ou mais
Anastomose Cirúrgica
Colectomia
Neoplasias Colorretais/mortalidade
Neoplasias Colorretais/patologia
Feminino
Seres Humanos
Itália/epidemiologia
Masculino
Meia-Idade
Neoplasias Primárias Múltiplas/mortalidade
Neoplasias Primárias Múltiplas/patologia
Segunda Neoplasia Primária/mortalidade
Segunda Neoplasia Primária/patologia
Prognóstico
Estudos Retrospectivos
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180125
[Lr] Data última revisão:
180125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.23750/abm.v88i1.6031


  9 / 12073 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28450182
[Au] Autor:Yu SC; Huang HH; Li CC; Tang JL; Lee YH; Mao TL; Kuo KT; Lin CT; Liu JH; Ko BS; Yao M
[Ad] Endereço:Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: b88401002@ntu.edu.tw.
[Ti] Título:Cervical Papanicolaou Smears in Hematopoietic Stem Cell Transplant Recipients: High Prevalence of Therapy-Related Atypia during the Acute Phase.
[So] Source:Biol Blood Marrow Transplant;23(8):1367-1373, 2017 Aug.
[Is] ISSN:1523-6536
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Hematopoietic stem cell transplant (HSCT) recipients have a higher risk of cervical cancer. Papanicolaou (Pap) smear is the standard tool for screening cervical cancer, but there is limited research about the cervical cytology in HSCT recipients. Here, we retrospectively included adult female patients who underwent allogeneic or autologous HSCT at National Taiwan University Hospital during 2009 to 2015 and reviewed their Pap smears before and after HSCT. There were 248 allogeneic and 131 autologous HSCT recipients in our study. In allogeneic HSCT recipients, 38.7% (96 of 248) had pre-HSCT Pap smears and 17.1% (44 of 248) had post-HSCT Pap smears. In the autologous HSCT recipients, 35.1% (46 of 131) had pre-HSCT Pap smears and 13.7% (18 of 131) had post-HSCT Pap smears. Compared with allogeneic HSCT recipients without post-HSCT Pap smears, more recipients with post-HSCT Pap smears received bone marrow-derived stem cells (18.2% versus 4.9% respectively; P = .0077) and had longer overall survival (median overall survival, not reached versus 22.1 months; P < .0001). The abnormal rates of post-HSCT Pap smear were 13% (6 of 44) and 11% (2 of 18) in allogeneic and autologous recipients respectively, higher than in the general Taiwanese population (1.22%). Infections were rare in post-HSCT Pap smears. Of note, 11% (5 of 44) of post-HSCT Pap smears from allogeneic recipients showed therapy-related atypia, manifesting as enlarged hyperchromatic nuclei, vacuolated cytoplasm, and occasional tadpole-like cells. These atypical cytological features mimic precancerous lesions, but cervical biopsies and human papilloma virus tests were negative. The atypical cytological features resolved spontaneously in the subsequent follow-up Pap smears. On average, Pap smears with therapy-related atypia were sampled at day +77, significantly earlier than those without therapy-related atypia (P = .016). Therapy-related atypia was more frequent in post-HSCT Pap smears sampled within 100 days after HSCT (before day +100, 4 of 5, 80%, versus after day +100, 1 of 39, 2.56%; P = .0002). The strong temporal relationship suggests these atypical cytological changes resulted from conditioning regimen, most likely busulfan-containing chemotherapy. No therapy-related atypia were observed after total body irradiation or nonbusulfan-containing chemotherapy. In conclusion, therapy-related atypia was common in post-HSCT Pap smears sampled within 100 days after HSCT. Clinical information is critical for correct cytological diagnosis.
[Mh] Termos MeSH primário: Bussulfano/efeitos adversos
Doenças Hematológicas
Transplante de Células-Tronco Hematopoéticas
Segunda Neoplasia Primária
Teste de Papanicolaou
Condicionamento Pré-Transplante/efeitos adversos
Neoplasias do Colo do Útero
Esfregaço Vaginal
[Mh] Termos MeSH secundário: Adulto
Idoso
Aloenxertos
Autoenxertos
Bussulfano/administração & dosagem
Intervalo Livre de Doença
Feminino
Doenças Hematológicas/mortalidade
Doenças Hematológicas/patologia
Doenças Hematológicas/terapia
Seres Humanos
Meia-Idade
Segunda Neoplasia Primária/diagnóstico
Segunda Neoplasia Primária/mortalidade
Segunda Neoplasia Primária/patologia
Estudos Retrospectivos
Taxa de Sobrevida
Neoplasias do Colo do Útero/diagnóstico
Neoplasias do Colo do Útero/etiologia
Neoplasias do Colo do Útero/mortalidade
Neoplasias do Colo do Útero/patologia
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
G1LN9045DK (Busulfan)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180125
[Lr] Data última revisão:
180125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  10 / 12073 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29200163
[Au] Autor:Hong KT; Choi JY; Hong CR; Kang HJ; Park KD; Shin HY
[Ad] Endereço:Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
[Ti] Título:Therapy-related Acute Myeloid Leukemia After the Treatment of Primary Solid Cancer in Children: A Single-center Experience.
[So] Source:J Pediatr Hematol Oncol;40(1):e23-e28, 2018 Jan.
[Is] ISSN:1536-3678
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Therapy-related acute myeloid leukemia (t-AML) has a dismal prognosis and is one of the most frequent second malignant neoplasms which could be encountered by pediatric oncologists. Between October 2000 and September 2016, 16 patients who had primary solid tumors were diagnosed with t-AML at the Seoul National University Children's Hospital. The median patient age at the time of diagnosis of their primary solid tumors was 9.6 years (range, 0.1 to 15.4 y), and that of t-AML was 14.0 years (range, 4.7 to 23.9 y). The median latency period from the end of the primary tumor treatment to the initial diagnosis of t-AML was 29 months (range, 6 to 130 mo). Twelve patients achieved complete remission. Of them, only 7 patients underwent hematopoietic stem cell transplantation (HSCT). The 3-year overall survival (OS) rates and event-free survival rates were 33.7±12.2% and 26.9±11.5% respectively. The patients who underwent HSCT showed favorable 5-year OS rates (57.1±18.7%), whereas the 5-year OS rates of those who did not undergo HSCT was 0%. This study demonstrates that an achievement of complete remission and a subsequent HSCT can be the optimal solution for the treatment of t-AML, and this strategy showed acceptable outcomes.
[Mh] Termos MeSH primário: Leucemia Mieloide Aguda/terapia
Segunda Neoplasia Primária/terapia
Neoplasias/complicações
[Mh] Termos MeSH secundário: Adolescente
Criança
Pré-Escolar
Intervalo Livre de Doença
Feminino
Transplante de Células-Tronco Hematopoéticas
Seres Humanos
Leucemia Mieloide Aguda/etiologia
Leucemia Mieloide Aguda/mortalidade
Masculino
Neoplasias/mortalidade
Segunda Neoplasia Primária/mortalidade
Indução de Remissão
Taxa de Sobrevida
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180112
[Lr] Data última revisão:
180112
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171205
[St] Status:MEDLINE
[do] DOI:10.1097/MPH.0000000000001019



página 1 de 1208 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde